Brainstorm Cell Therapeutics Inc (BCLI) stock price

Brainstorm Cell Therapeutics Inc (BCLI) is a Healthcare · Biotechnology company listed on NASDAQ. Price $0.98 (+0.10%), Market cap $0.01B, 52-week low–high $0.48 ~ $1.31.

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company's NurOwn proprietary cell therapy platform that leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is involved in the development of NurOwn, which has completed Phase IIIb clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the t

Key metrics

Financial statements, price targets, institutional (13F) holdings and related news for Brainstorm Cell Therapeutics Inc are updated in real time on BlackAll Trade.

Brainstorm Cell Therapeutics Inc financial summary

Analyst outlook

Key ratios · profitability · growth

Frequently asked questions

What is the current Brainstorm Cell Therapeutics Inc (BCLI) stock price?

Brainstorm Cell Therapeutics Inc trades at $0.98 (+0.10%). Real-time quotes and charts are available on BlackAll Trade.

What is the Brainstorm Cell Therapeutics Inc (BCLI) market cap?

Brainstorm Cell Therapeutics Inc has a market cap of about $0.01B.

What does Brainstorm Cell Therapeutics Inc (BCLI) do?

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The compa